ContractSafety Agreement • June 27th, 2013 • Iroko Pharmaceuticals Inc. • Pharmaceutical preparations • England and Wales
[***] indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this agreement, including redacted portions so indicated, has been filed separately with the Securities and Exchange Commission.
ContractManufacturing and Supply Agreement • June 27th, 2013 • Iroko Pharmaceuticals Inc. • Pharmaceutical preparations • England and Wales
[***] indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this agreement, including redacted portions so indicated, has been filed separately with the Securities and Exchange Commission.
CAPITAL PROJECT AGREEMENTIroko Pharmaceuticals Inc. • June 27th, 2013 • Pharmaceutical preparations • Pennsylvania
This Agreement (the “Agreement”), is effective May 10, 2012 (the “Effective Date”) and is made by and between Iroko Pharmaceuticals, LLC, a Delaware limited liability company, whose principal place of business is at The Navy Yard Corporate Center, One Crescent Drive, Suite 400, Philadelphia, Pennsylvania 19112 (“Iroko”) and Catalent CTS, Inc., formerly known as Aptuit, Inc., a Delaware corporation, with offices located at 10245 Hickman Mills Drive, Kansas City, MO 64137 (“Catalent”).
